Fidelity's passive stake remains stable at 15%, with a negligible increase of ~4,100 shares since the prior filing. No signal of activist intent. Monitor whether Fidelity converts to a 13D filing if it engages with management on strategic direction, particularly around the planned ZYNQUISTA NDA resubmission in Q1 2027.
LXRX drugs
LXRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $1.61entry
- T+1 · 11d ago +10.56%α +10.25% · $1.78
- T+5 · 5d ago +13.04%α +9.75% · $1.82
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fidelity (FMR LLC) filed an amended Schedule 13G reporting beneficial ownership of 66,743,389.66 shares of Lexicon Pharmaceuticals common stock as of September 30, 2026, representing 15.0% of shares outstanding. This is an increase from the prior filing (August 2026) which reported 66,739,266 shares at 15.0%, indicating a modest net addition of about 4,124 shares. The filing is routine for a passive institutional holder and coincides with Lexicon's Q3 2026 earnings release showing declining revenue and a wider net loss.
Key Financial Metrics
Key Facts
- FMR LLC reported beneficial ownership of 66,743,389.66 shares of Lexicon Pharmaceuticals common stock as of September 30, 2026
- The stake represents 15.0% of shares outstanding
- This is an amendment to a Schedule 13G, indicating passive investment intent
- The filing date is November 5, 2026, the same day as Lexicon's Q3 2026 earnings release
- Fidelity Growth Company Commingled Pool held 29,155,748 shares (6.6%) of the total outstanding as of September 30, 2026
Financial Impact
FMR LLC holds 66.7M shares valued at approximately $97M based on $650M market cap and 15% stake
Risk Factors
- Fidelity's large 15% stake creates overhang risk if it decides to reduce its position
- The filing coincides with a weak Q3 earnings report (revenue down 20% YoY, wider net loss), which could prompt institutional reassessment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002771 |
| Document: 0000315066-26-002771-index-headers.html | 0000315066-26-002771 |
| Document: 0000315066-26-002771-index.html | 0000315066-26-002771 |
| Document: 0000315066-26-002771.txt | 0000315066-26-002771 |
Track record
16 reports on LXRX
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers